Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16157098 | 0.83 | EGFR (0.65) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL16157019 | 0.81 | NPC1 (0.68) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL16157058 | 0.78 | NPC1 (0.61) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL16157031 | 0.71 | EGFR (0.70) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL16157084 | 0.71 | EGFR (0.70) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL6954402 | 0.67 | BCHE (0.56) | NPSR1ALDH1A1 | |
| SCHEMBL14603763 | 0.67 | GSK3B (0.80) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL16157024 | 0.67 | NPC1 (1.00) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL14553085 | 0.67 | NPC1 (0.85) | SMN1; SMN2RAB9AHPGDL3MBTL1NPC1 | |
| SCHEMBL29051282 | 0.67 | NPC1 (0.40) | SMN1; SMN2RAB9AHPGDNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | GOT2, G6PD, FNTB | SMN1; SMN2 4593/4885RAB9A 3054/4885HPGD 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.